Patents by Inventor Norimasa Iwasaki

Norimasa Iwasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066152
    Abstract: The present invention provides: an MRI contrast agent for detecting cartilage damage, which comprises 17O-labeled water; and a method and a program for detecting cartilage damage using the contrast agent. According to the present invention, it becomes possible to detect a damage in a cartilage, particularly a minor damage in the surface layer of a cartilage which has been difficult to detect so far, by using 17O-labeled water as a contrast agent.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 29, 2024
    Inventors: Tomohiro ONODERA, Kohsuke KUDO, Yoshiaki HOSOKAWA, Norimasa IWASAKI, Hiroyuki KAMEDA
  • Publication number: 20230080690
    Abstract: Provided is a composition for treating cartilage injury lesion that is combined with a concentrated bone marrow aspirate and applied to a cartilage injury lesion, that has flowability when applied to the cartilage injury lesion, and that contains a monovalent metal salt of alginic acid. Thereby, a novel composition for treating cartilage injury lesion that can be used to restore and/or regenerate cartilage tissue is provided.
    Type: Application
    Filed: January 15, 2021
    Publication date: March 16, 2023
    Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., Ltd.
    Inventors: Norimasa IWASAKI, Tomohiro ONODERA, Atsushi URITA, Ryo JO
  • Publication number: 20230045844
    Abstract: Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.
    Type: Application
    Filed: January 13, 2021
    Publication date: February 16, 2023
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Tomokazu TAKAI, Hitoshi MIZUNO, Akira TAKAHASHI, Toshiya ENDO, Shinichi SAKAUE, Norimasa IWASAKI, Tomohiro ONODERA, Koji IWASAKI
  • Publication number: 20230041137
    Abstract: A retractor is provided that can form a joint cavity internal space for a field of view for an endoscope and practice of a treatment in a state where a wound area is spread. A retractor includes first arm portions 2 and 3 and a second arm portion 4 positioned between the first arm portions 2 and 3. The first arm portions 2 and 3 include first claw portions 12 and 13 to be hung on a wound area entrance edge. The second arm portion 4 includes a second claw portion 14 to be hung on the wound area entrance edge. When the first arm portions 2 and 3 and the second arm portion 4 are in a closed state, the first claw portions 12 and 13 and the second claw portion 14 overlap with each other.
    Type: Application
    Filed: January 13, 2021
    Publication date: February 9, 2023
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Hitoshi MIZUNO, Kuniyoshi MASUDA, Masahiko KATAYAMA, Tomokazu TAKAI, Toshiya ENDO, Norimasa IWASAKI, Tomohiro ONODERA, Koji IWASAKI
  • Patent number: 11426425
    Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 30, 2022
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Eiji Kondo, Norimasa Iwasaki, Tomohiro Onodera, Wooyoung Kim, Yasuyuki Kawaguchi
  • Publication number: 20200289547
    Abstract: The present invention provides a composition for filling the nucleus pulposus of an intervertebral disc, the composition containing a low endotoxin monovalent metal salt of alginic acid. The composition is applied to a nucleus pulposus site of a subject, is used so as to be cured partially after application, and has fluidity when applied to the nucleus pulposus site. Accordingly, a composition for filling nucleus pulposus is provided, the composition being capable of promoting the regeneration of the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: January 27, 2017
    Publication date: September 17, 2020
    Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., Ltd
    Inventors: Hideki SUDO, Takeru TSUJIMOTO, Norimasa IWASAKI, Satoshi SHIMIZU, Mitsuko ISAJI
  • Publication number: 20200030367
    Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 30, 2020
    Applicants: Mochida Pharmaceutical Co., Ltd, National University Corporation Hokkaido University
    Inventors: Eiji KONDO, Norimasa IWASAKI, Tomohiro ONODERA, Wooyoung KIM, Yasuyuki KAWAGUCHI
  • Patent number: 9821027
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: November 21, 2017
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Atsushi Sukegawa, Akio Minami, Nobuo Ohzawa
  • Publication number: 20160067309
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Applicants: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa IWASAKI, Atsushi SUKEGAWA, Akio MINAMI, Nobuo OHZAWA
  • Patent number: 9216201
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 22, 2015
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Fumiyoshi Kasahara, Chihiro Miyajima, Nobuo Ohzawa, Mariko Imai
  • Publication number: 20140213524
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Application
    Filed: August 22, 2012
    Publication date: July 31, 2014
    Inventors: Norimasa Iwasaki, Atsushi Sukegawa, Akio Minami, Nobuo Ohzawa
  • Patent number: 8372394
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: February 12, 2013
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Fumiyoshi Kasahara, Chihiro Miyajima, Nobuo Ohzawa, Mariko Imai
  • Patent number: 8367637
    Abstract: The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for treating a joint disease which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing cartilage injuries, suppressing inflammation and pain of joint tissue, inhibiting degeneration of synovial tissue, and inhibiting osteochondral destruction.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 5, 2013
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Nobuo Ohzawa, Mariko Imai
  • Publication number: 20100048506
    Abstract: The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for treating a joint disease which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing cartilage injuries, suppressing inflammation and pain of joint tissue, inhibiting degeneration of synovial tissue, and inhibiting osteochondral destruction.
    Type: Application
    Filed: August 19, 2009
    Publication date: February 25, 2010
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Nobuo Ohzawa, Mariko Imai
  • Publication number: 20100015102
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Application
    Filed: February 21, 2008
    Publication date: January 21, 2010
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Fumiyoshi Kasahara, Chihiro Miyajima, Nobuo Ohzawa, Mariko Imai
  • Publication number: 20060134158
    Abstract: It is intended to provide a three-dimensional scaffolds appropriate for culturing animal cells such as chondrocytes and fibroblasts. These three-dimensional scaffolds which comprise a chitosan/acidic biopolymers hybrid fibers composed of chitosan or its salts in the inside of the fiber and complexes of chitosan with biodegradable acidic biopolymers coating the fiber surface, are made of fibers capable of retaining their shapes after allowing to stand Dulbecco's modified Eagle's medium (DMEM) containing 10% of FBS (fetal bovine serum) at room temperature for 2 weeks.
    Type: Application
    Filed: June 26, 2003
    Publication date: June 22, 2006
    Applicant: Chemical Biology Institute
    Inventors: Tokifumi Majima, Norimasa Iwasaki, Tadanao Funakoshi, Akio Minami, Shin-ichiro Nishimura, Seiichi Tokura, Kazuo Harada, Sachiko Nonaka, Nobuhiki Maekawa